MEA Taxane Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144129
- Pages: 225
-
Format:
Short Description
Middle East and Africa Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (Saudi Arabia, UAE, Egypt, Israel, South Africa, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as inhibitors of mitosis and which are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, breast cancer, Kaposi's sarcoma, gastric cancer, bladder cancer, esophageal cancer and other carcinomas are all commonly treated with paclitaxel and docetaxel. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Market Segmentation:
The Middle East and Africa taxane market is categorized into seven notable segments which are based type, drug type, formulation, age group, application, end user and distribution channel.
On the basis of type, the Middle East and Africa taxane market is segmented into paclitaxel, docetaxel and cabazitaxel
On the basis of drug type, the Middle East and Africa taxane market is segmented into branded and generics
On the basis of formulation, the Middle East and Africa taxane market is segmented into liposomes, nanoparticles, polymeric micelles, others
On the basis of age group, the Middle East and Africa taxane market is segmented into adults and geriatric
On the basis of application, the Middle East and Africa taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and others
On the basis of end user, the Middle East and Africa taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
On the basis of distribution channel, the Middle East and Africa taxane market is segmented into direct tender, retail sales
Market Players
Some of the major players operating in the Middle East and Africa taxane market are:
Viatris Inc.
Sandoz International GmbH (A Novartis Division)
sanofi-aventis U.S. LLC
Hikma Pharmaceuticals PLC
Pfizer Inc.
Dr. Reddys Laboratories Ltd.
Bristol-Myers Squibb Company
Cipla Inc.
Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF MIDDLE EAST & AFRICA TAXANE MARKET 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 MARKET APPLICATION COVERAGE GRID 52
2.8 TYPE LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHT 62
4.1 PESTEL_ANALYSIS 63
4.2 PORTER'S FIVE FORCES MODEL 64
5 EPIDEMIOLOGY 65
6 INDUSTRIAL INSIGHTS 66
6.1 CONCLUSION 67
7 MIDDLE EAST & AFRICA TAXANE MARKET: REGULATIONS 68
8 MARKET OVERVIEW 73
8.1 DRIVERS 75
8.1.1 THE RISE IN INCIDENCE OF CANCER 75
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT 76
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS 76
8.1.4 USE OF REIMBURSEMENT FOR TAXANE 77
8.2 RESTRAINTS 77
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS 77
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT 78
8.2.3 RISE IN PRODUCT RECALLS 78
8.3 OPPORTUNITIES 79
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 79
8.3.2 RISE IN HEALTHCARE EXPENDITURE 79
8.4 CHALLENGES 80
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT 80
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT 80
9 MIDDLE EAST & AFRICA TAXANE MARKET, BY TYPE 82
9.1 OVERVIEW 83
9.2 PACLITAXEL 86
9.2.1 BY TYPE 86
9.2.1.1 SEMI-SYNTHETIC 87
9.2.1.2 NATURAL 87
9.2.2 BY STRENGTH 87
9.2.2.1 100MG 87
9.2.2.2 200MG 87
9.2.2.3 250MG 87
9.2.2.4 30MG 87
9.2.2.5 260MG 87
9.2.2.6 300MG 88
9.3 DOCETAXEL 88
9.3.1 120MG 89
9.3.2 80MG 89
9.3.3 20MG 89
9.3.4 40MG 89
9.3.5 60MG 89
9.4 CABAZITAXEL 89
9.4.1 60MG 90
10 MIDDLE EAST & AFRICA TAXANE MARKET, BY APPLICATION 91
10.1 OVERVIEW 92
10.2 BREAST CANCER 95
10.3 NON-SMALL CELL LUNG CANCER 95
10.4 PANCREATIC CANCER 96
10.5 OVARIAN CANCER 97
10.6 PROSTATE CANCER 97
10.7 OTHERS 98
11 MIDDLE EAST & AFRICA TAXANE MARKET, BY DRUG TYPE 99
11.1 OVERVIEW 100
11.2 GENERICS 103
11.3 BRANDED 104
12 MIDDLE EAST & AFRICA TAXANE MARKET, BY FORMULATION 105
12.1 OVERVIEW 106
12.2 LIPOSOMES 109
12.3 NANOPARTICLES 109
12.4 POLYMERIC MICELLES 110
12.5 OTHERS 111
13 MIDDLE EAST & AFRICA TAXANE MARKET, BY AGE GROUP 112
13.1 OVERVIEW 113
13.2 ADULT 116
13.2.1 FEMALE 117
13.2.2 MALE 117
13.3 GERIATRIC 117
13.3.1 FEMALE 118
13.3.2 MALE 118
14 MIDDLE EAST & AFRICA TAXANE MARKET, BY END USER 119
14.1 OVERVIEW 120
14.2 HOSPITALS 123
14.3 AMBULATORY SURGICAL CENTERS 123
14.4 SPECIALTY CLINICS 124
14.5 OTHERS 125
15 MIDDLE EAST & AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL 126
15.1 OVERVIEW 127
15.2 RETAIL SALES 130
15.2.1 HOSPITAL PHARMACY 130
15.2.2 RETAIL PHARMACY 131
15.2.3 ONLINE PHARMACY 131
15.3 DIRECT TENDER 131
16 MIDDLE EAST & AFRICA TAXANE MARKET, BY REGION 132
16.1 MIDDLE EAST AND AFRICA 133
16.1.1 SOUTH AFRICA 142
16.1.2 EGYPT 146
16.1.3 SAUDI ARABIA 150
16.1.4 U.A.E 154
16.1.5 ISRAEL 158
16.1.6 KUWAIT 162
16.1.7 REST OF MIDDLE EAST AND AFRICA 166
17 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY LANDSCAPE 167
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 167
18 SWOT ANALYSIS 168
19 COMPANY PROFILE 169
19.1 BRISTOL-MYERS SQUIBB COMPANY 169
19.1.1 COMPANY SNAPSHOT 169
19.1.2 REVENUE ANALYSIS 169
19.1.3 COMPANY SHARE ANALYSIS 170
19.1.4 PRODUCT PORTFOLIO 170
19.1.5 RECENT DEVELOPMENTS 170
19.2 SANOFI-AVENTIS U.S. LLC 172
19.2.1 COMPANY SNAPSHOT 172
19.2.2 REVENUE ANALYSIS 172
19.2.3 COMPANY SHARE ANALYSIS 173
19.2.4 PRODUCT PORTFOLIO 173
19.2.5 RECENT DEVELOPMENTS 173
19.3 VIATRIS INC. 175
19.3.1 COMPANY SNAPSHOT 175
19.3.2 REVENUE ANALYSIS 175
19.3.3 COMPANY SHARE ANALYSIS 176
19.3.4 PRODUCT PORTFOLIO 176
19.3.5 RECENT DEVELOPMENT 176
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION) 177
19.4.1 COMPANY SNAPSHOT 177
19.4.2 REVENUE ANALYSIS 177
19.4.3 COMPANY SHARE ANALYSIS 178
19.4.4 PRODUCT PORTFOLIO 178
19.4.5 RECENT DEVELOPMENTS 179
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA ) 180
19.5.1 COMPANY SNAPSHOT 180
19.5.2 REVENUE ANALYSIS 180
19.5.3 COMPANY SHARE ANALYSIS 181
19.5.4 PRODUCT PORTFOLIO 181
19.5.5 RECENT DEVELOPMENTS 181
19.6 HIKMA PHARMACEUTICALS PLC 183
19.6.1 COMPANY SNAPSHOT 183
19.6.2 REVENUE ANALYSIS 183
19.6.3 PRODUCT PORTFOLIO 184
19.6.4 RECENT DEVELOPMENTS 184
19.7 ACCORD HEALTHCARE 185
19.7.1 COMPANY SNAPSHOT 185
19.7.2 PRODUCT PORTFOLIO 185
19.7.3 RECENT DEVELOPMENTS 185
19.8 AQVIDA GMBH 186
19.8.1 COMPANY SNAPSHOT 186
19.8.2 PRODUCT PORTFOLIO 186
19.8.3 RECENT DEVELOPMENTS 186
19.9 AUREATE HEALTHCARE 187
19.9.1 COMPANY SNAPSHOT 187
19.9.2 PRODUCT PORTFOLIO 187
19.9.3 RECENT DEVELOPMENTS 187
19.10 CIPLA INC. 188
19.10.1 COMPANY SNAPSHOT 188
19.10.2 REVENUE ANALYSIS 188
19.10.3 PRODUCT PORTFOLIO 189
19.10.4 RECENT DEVELOPMENTS 189
19.11 DR. REDDYS LABORATORIES LTD. 190
19.11.1 COMPANY SNAPSHOT 190
19.11.2 REVENUE ANALYSIS 190
19.11.3 PRODUCT PORTFOLIO 191
19.11.4 RECENT DEVELOPMENTS 191
19.12 ELEVAR THERAPEUTICS 192
19.12.1 COMPANY SNAPSHOT 192
19.12.2 PRODUCT PORTFOLIO 192
19.12.3 RECENT DEVELOPMENTS 192
19.13 HETERO HEALTHCARE LIMITED. 194
19.13.1 COMPANY SNAPSHOT 194
19.13.2 PRODUCT PORTFOLIO 194
19.13.3 RECENT DEVELOPMENTS 194
19.14 HUIANG PHARMACEUTICAL CO LTD 195
19.14.1 COMPANY SNAPSHOT 195
19.14.2 PRODUCT PORTFOLIO 195
19.14.3 RECENT DEVELOPMENTS 195
19.15 INGENUS PHARMACEUTICALS, LLC 196
19.15.1 COMPANY SNAPSHOT 196
19.15.2 PRODUCT PORTFOLIO 196
19.15.3 RECENT DEVELOPMENTS 196
19.16 LUYE PHARMA GROUP 197
19.16.1 COMPANY SNAPSHOT 197
19.16.2 REVENUE ANALYSIS 197
19.16.3 PRODUCT PORTFOLIO 198
19.16.4 RECENT DEVELOPMENTS 198
19.17 PANACEA BIOTEC 199
19.17.1 COMPANY SNAPSHOT 199
19.17.2 REVENUE ANALYSIS 199
19.17.3 PRODUCT PORTFOLIO 200
19.17.4 RECENT DEVELOPMENTS 200
19.18 PFIZER INC. 201
19.18.1 COMPANY SNAPSHOT 201
19.18.2 REVENUE ANALYSIS 201
19.18.3 PRODUCT PORTFOLIO 202
19.18.4 RECENT DEVELOPMENTS 202
19.19 RPG LIFE SCIENCES LIMITED 203
19.19.1 COMPANY SNAPSHOT 203
19.19.2 REVENUE ANALYSIS 203
19.19.3 PRODUCT PORTFOLIO 204
19.19.4 RECENT DEVELOPMENTS 204
19.20 SAMARTH LIFE SCIENCES PVT. LTD. 205
19.20.1 COMPANY SNAPSHOT 205
19.20.2 PRODUCT PORTFOLIO 205
19.20.3 RECENT DEVELOPMENTS 205
19.21 SAMYANG HOLDINGS CORPORATION. 206
19.21.1 COMPANY SNAPSHOT 206
19.21.2 REVENUE ANALYSIS 206
19.21.3 PRODUCT PORTFOLIO 207
19.21.4 RECENT DEVELOPMENTS 207
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC. 208
19.22.1 COMPANY SNAPSHOT 208
19.22.2 PRODUCT PORTFOLIO 208
19.22.3 RECENT DEVELOPMENTS 208
19.23 TORRENT PHARMACEUTICALS LTD 209
19.23.1 COMPANY SNAPSHOT 209
19.23.2 REVENUE ANALYSIS 209
19.23.3 PRODUCT PORTFOLIO 210
19.23.4 RECENT DEVELOPMENTS 210
19.24 TAXANE HEALTHCARE 211
19.24.1 COMPANY SNAPSHOT 211
19.24.2 PRODUCT PORTFOLIO 211
19.24.3 RECENT DEVELOPMENTS 211
20 QUESTIONNAIRE 212
21 RELATED REPORTS 215
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
